Get your health question answered instantly from our pool of 18000+ doctors from over 80 specialties
152 Doctors Online

By proceeding, I accept the Terms and Conditions

Dr. Andrew Rynne
MD
Dr. Andrew Rynne

Family Physician

Exp 50 years

HCM Blog Instant Access to Doctors
HCM BlogQuestions Answered
HCM Blog Satisfaction

Should Mismatched Allogeneic SCT Be Used For Treatment?

My husband was dx'd with Stage IVB Hodgkins 9-09. He has had 2 chemo regimes (his disease became refractory after both courses) and an autologous SCT preceded by high dose chemo in Sept. of last year. He had a (-) PET scan in Nov. Unfortunately he has now relapsed with mets to the liver. His hem/onc has recommended a mismatched allogeneic SCT using his sister's cells which is a 50% match to his. Do you think this is a reasonable course? Also could you tell me what end stage Hodgkins with liver involvement would be like if he fails to obtain remission if he proceeds with the transplant. Thank you in advance.
Thu, 22 Nov 2018
Report Abuse
Oncologist 's  Response
Hello,

Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative option for a variety of malignant and non-malignant haematological and congenital diseases.

Due to the fact that the human leukocyte antigen system is inherited independently of the blood group system, approximately 40-50% of all HSCTs are performed across the ABO blood group barrier.

Hope I have answered your query. Let me know if I can assist you further.

Take care

Regards,
Dr Esmeralda Sera, Oncologist
I find this answer helpful
Disclaimer: These answers are for your information only and not intended to replace your relationship with your treating physician.
This is a short, free answer. For a more detailed, immediate answer, try our premium service [Sample answer]
Share on
 

Related questions you may be interested in

Recent questions on Allotransplantation


Loading Online Doctors....
Should Mismatched Allogeneic SCT Be Used For Treatment?

Hello, Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative option for a variety of malignant and non-malignant haematological and congenital diseases. Due to the fact that the human leukocyte antigen system is inherited independently of the blood group system, approximately 40-50% of all HSCTs are performed across the ABO blood group barrier. Hope I have answered your query. Let me know if I can assist you further. Take care Regards, Dr Esmeralda Sera, Oncologist